Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus.
The immunomodulatory effects of liposomal amphotericin B (LAMB), amphotericin B lipid complex, and amphotericin B colloidal dispersion (ABCD) on antifungal activity of human monocytes (MNCs), an important component of antifungal host defense, against Aspergillus fumigatus were compared to those of deoxycholate amphotericin B (DAMB). MNCs from healthy volunteers were incubated with 1 or 5 microg/ml DAMB and 5 or 25 microg/ml lipid formulations for 22 h. Drug-pretreated or untreated MNCs were then washed and assayed for the following: (i) activity against A. fumigatus hyphae by XTT assay at MNC:hypha ratios of 10:1 and 20:1; (ii) production of superoxide anion (O2-) from MNCs in response to hyphae by cytochrome c reduction; (iii) production of hydrogen peroxide (H2O2) and H2O2-dependent intracellular intermediates (DIIs), such as OH- and HOCl, from MNCs in response to A. fumigatus culture supernatant by flow cytometric measurement of dihydrorhodamine-1,2,3 oxidation. With the exception of 1 microg/ml DAMB and 5 mug/ml LAMB or ABCD at 10:1, all amphotericin B formulations at both concentrations and MNC:hypha ratios enhanced MNC-induced damage of A. fumigatus hyphae compared to results with untreated cells (P < 0.01). While MNC O2- production upon hyphal challenge, an early event in oxidative burst, was not affected by the drugs, production of H2O2 and DIIs, late events, were significantly increased by all four drugs (P < 0.01). At clinically relevant concentrations, both conventional amphotericin B and its lipid formulations enhance antihyphal activity of MNCs against A. fumigatus in association with significant augmentation of H2O2 and DIIs but not O2-, further demonstrating the immunomodulatory antifungal activities of these agents.
Dotis
J
J
Laboratory of Infectious Diseases, 3rd Department of Pediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-546 42 Thessaloniki, Greece.
Simitsopoulou
M
M
Dalakiouridou
M
M
Konstantinou
T
T
Taparkou
A
A
Kanakoudi-Tsakalidou
F
F
Walsh
T J
TJ
Roilides
E
E
D000666:Amphotericin B / Q000737:chemistry / Q000494:pharmacology*; D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology*; D001232:Aspergillus fumigatus / Q000187:drug effects*; D002626:Chemistry, Pharmaceutical / Q000379:methods; D003102:Colloids; D003840:Deoxycholic Acid; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D025301:Hyphae / Q000187:drug effects; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000378:metabolism; D008081:Liposomes; D013481:Superoxides / Q000378:metabolism
D000935:Antifungal Agents; D003102:Colloids; D008081:Liposomes; D003840:Deoxycholic Acid; D013481:Superoxides; D000666:Amphotericin B; D006861:Hydrogen Peroxide